Jonosteril Hd5 (Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride, Calcium Chloride Dihydrate, Glu)

The solution provides essential ions—sodium, potassium, calcium, magnesium—and glucose directly into the bloodstream. These components restore normal plasma concentrations, support cellular function, and help maintain osmotic balance, thereby correcting electrolyte disturbances and supporting circulatory volume.

The dose of Jonosteril HD5 is determined by the prescribing clinician based on the patient’s electrolyte levels, fluid status, weight and clinical condition. The healthcare professional calculates the appropriate volume and infusion rate for each individual case.

Safety data for Jonosteril HD5 in pregnancy and lactation are limited. The product should be used only if clearly needed and after a risk‑benefit assessment by the treating physician. Consultation with a specialist is recommended before administration to pregnant or nursing patients.

To order Jonosteril HD5, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Jonosteril HD5 offers a balanced combination of sodium, potassium, calcium, magnesium and glucose in a single formulation, which can reduce the need for multiple separate infusions. Compared with simpler saline solutions, it provides broader electrolyte coverage, making it suitable for complex resuscitation scenarios where multiple deficiencies are present.

Jonosteril HD5 should be stored at controlled room temperature, protected from light and moisture, and kept in its original packaging until use. Do not freeze the solution. Inspect the container for any damage before administration.

Jonosteril HD5 is administered intravenously. The solution is infused through a sterile IV line, with the rate and total volume determined by the prescribing clinician according to the patient’s clinical needs and laboratory results.

The most serious risks include severe electrolyte imbalance, which can lead to cardiac arrhythmias, and rare anaphylactic reactions. Continuous monitoring of electrolyte levels, cardiac rhythm and vital signs during infusion helps mitigate these risks.

Jonosteril HD5 should be avoided in patients with known hypersensitivity to any of its components, in those with uncontrolled hyperkalemia, hypermagnesemia, hypercalcemia, or severe fluid overload unless closely monitored. Clinicians must assess each patient’s condition before initiating therapy.